Sarepta Therapeutics | SRPT - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amgen USD 1.72B 134M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Capricor Therapeutics USD 1.92M 446.47K 2025-12
Daiichi Sankyo JPY 249.96B 21.73B 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
Incyte USD 351.73M 23.64M 2026-06
Insmed USD 247.47M 208K 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Moderna USD 216M 43M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.63B 307M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Tectonic Therapeutic USD 6.43M 2.99M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06